Pathological Complete Response Following mFOLFOX6 Plus Zolbetuximab and Conversion Surgery in Initially Unresectable CLDN18.2-Positive Advanced Gastric Cancer: A Case Report
Journal of Gastrointestinal Cancer · 25.07.2026 · 57 (1)
DOI: 10.1007/s12029-026-01546-3 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Gastrointestinal Cancer, online erschienen am 25.07.2026. Verfasst von Tamotsu Sagawa und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, National Hospital Organization Hokkaido Cancer Center, 3-54 Kikusui 4-jo 2-chome, Shiroishi-ku, Sapporo-shi, Hokkaido…. Hauptthemen laut MEDLINE: Stomach Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 14 Literaturangaben.
Abstract (Originalsprache)
Zolbetuximab plus platinum-fluoropyrimidine chemotherapy has emerged as an important first-line treatment option for patients with claudin 18.2 (CLDN18.2)-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma. However, pathological complete response after zolbetuximab-based induction therapy followed by conversion surgery has rarely been documented, particularly in patients with peritoneal dissemination and malignant ascites. A man in his early 50s with Eastern Cooperative Oncology Group performance status 0 was referred to our hospital with scirrhous-type gastric cancer. Initial evaluation revealed initially unresectable advanced gastric cancer with peritoneal dissemination and cytologically confirmed malignant ascites. Gastric biopsy showed poorly differentiated adenocarcinoma with signet-ring cell features. The tumor was HER2 IHC 1+, strongly CLDN18.2-positive by the VENTANA CLDN18 (43–14 A) RxDx Assay, with 90% of viable tumor cells showing 2+/3 + membranous staining, proficient mismatch repair, and PD-L1 CPS ≥ 10. First-line mFOLFOX6 plus zolbetuximab was administered every 2 weeks without dose reduction or treatment delay. After six cycles, computed tomography and esophagogastroduodenoscopy showed marked improvement. After nine cycles, conversion surgery with total gastrectomy, D2 lymph node dissection, and Roux-en-Y reconstruction was performed. Intraoperative lavage cytology was negative. Final pathology showed ypT0N0, 0/20 lymph nodes, and TRG 1a/Grade 3, consistent with pathological complete response. This case suggests that mFOLFOX6 plus zolbetuximab may induce deep radiological, endoscopic, cytological, and pathological responses and may enable R0 conversion surgery in carefully selected patients with CLDN18.2-positive initially unresectable advanced gastric cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, National Hospital Organization Hokkaido Cancer Center, 3-54 Kikusui 4-jo 2-chome, Shiroishi-ku, Sapporo-shi, Hokkaido, 003-0804, Japan. stamotsu@jk9.so-net.ne.jp.
- Department of Advanced Medical Development, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
- Division of Medical Oncology, Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan.
- Department of Gastroenterological Surgery, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan.
- Department of Diagnostic Pathology, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan.
- Department of Gastroenterology, National Hospital Organization Hokkaido Cancer Center, 3-54 Kikusui 4-jo 2-chome, Shiroishi-ku, Sapporo-shi, Hokkaido, 003-0804, Japan.
Zitieren
APA
Sagawa, T., Oiwa, S., Hirakawa, M., Minagawa, N., Yoshida, M., Miyaishi, R., Uesugi, A., Okazaki, Y., Kawamura, K., Maeda, Y., Nagashima, H., & Fujikawa, K. (2026). Pathological Complete Response Following mFOLFOX6 Plus Zolbetuximab and Conversion Surgery in Initially Unresectable CLDN18.2-Positive Advanced Gastric Cancer: A Case Report. Journal of Gastrointestinal Cancer, 57(1). https://doi.org/10.1007/s12029-026-01546-3
Vancouver
Sagawa T, Oiwa S, Hirakawa M, Minagawa N, Yoshida M, Miyaishi R, et al. Pathological Complete Response Following mFOLFOX6 Plus Zolbetuximab and Conversion Surgery in Initially Unresectable CLDN18.2-Positive Advanced Gastric Cancer: A Case Report. Journal of Gastrointestinal Cancer. 2026;57(1). doi:10.1007/s12029-026-01546-3
BibTeX
@article{Sagawa2026,
author = {Sagawa, Tamotsu and Oiwa, Shutaro and Hirakawa, Masahiro and Minagawa, Nozomi and Yoshida, Makoto and Miyaishi, Riku and Uesugi, Atsushi and Okazaki, Yutaro and Kawamura, Kentaro and Maeda, Yoshiaki and Nagashima, Hiroyuki and Fujikawa, Koshi},
title = {Pathological Complete Response Following mFOLFOX6 Plus Zolbetuximab and Conversion Surgery in Initially Unresectable CLDN18.2-Positive Advanced Gastric Cancer: A Case Report},
journal = {Journal of Gastrointestinal Cancer},
year = {2026},
volume = {57},
number = {1},
doi = {10.1007/s12029-026-01546-3}
}
EUVIMED